What is Lonasen used for?

Lonasen is indicated for Schizophrenia.

Lonasen is developed by Dainippon Sumitomo Pharma Co., Ltd..

What development phase is Lonasen in?

Lonasen is FDA-approved (marketed).

What is the generic name of Lonasen?

BLONANSERIN is the generic (nonproprietary) name of Lonasen.

Last reviewed 2026-04-20 · How we verify

Lonasen (BLONANSERIN)

Dainippon Sumitomo Pharma Co., Ltd. · FDA-approved approved Small molecule Quality 17/100

At a glance

Generic name	BLONANSERIN
Sponsor	Dainippon Sumitomo Pharma Co., Ltd.
Drug class	blonanserin
Target	D(2) dopamine receptor
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved
First approval	2008

Approved indications

Schizophrenia

Common side effects

No common side effects on file.

Key clinical trials

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients (PHASE4)
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Lonasen CI brief — competitive landscape report
Lonasen updates RSS · CI watch RSS
Dainippon Sumitomo Pharma Co., Ltd. portfolio CI